245 related articles for article (PubMed ID: 35132719)
21. Detection of grey matter microstructural substrates of neurodegeneration in multiple sclerosis.
Krijnen EA; Russo AW; Salim Karam E; Lee H; Chiang FL; Schoonheim MM; Huang SY; Klawiter EC
Brain Commun; 2023; 5(3):fcad153. PubMed ID: 37274832
[TBL] [Abstract][Full Text] [Related]
22. Cognitive impairment in early MS: contribution of white matter lesions, deep grey matter atrophy, and cortical atrophy.
Engl C; Tiemann L; Grahl S; Bussas M; Schmidt P; Pongratz V; Berthele A; Beer A; Gaser C; Kirschke JS; Zimmer C; Hemmer B; Mühlau M
J Neurol; 2020 Aug; 267(8):2307-2318. PubMed ID: 32328718
[TBL] [Abstract][Full Text] [Related]
23. Cortical axonal loss is associated with both gray matter demyelination and white matter tract pathology in progressive multiple sclerosis: Evidence from a combined MRI-histopathology study.
Kiljan S; Preziosa P; Jonkman LE; van de Berg WD; Twisk J; Pouwels PJ; Schenk GJ; Rocca MA; Filippi M; Geurts JJ; Steenwijk MD
Mult Scler; 2021 Mar; 27(3):380-390. PubMed ID: 32390507
[TBL] [Abstract][Full Text] [Related]
24. New and enlarging white matter lesions adjacent to the ventricle system and thalamic atrophy are independently associated with lateral ventricular enlargement in multiple sclerosis.
Sinnecker T; Ruberte E; Schädelin S; Canova V; Amann M; Naegelin Y; Penner IK; Müller J; Kuhle J; Décard B; Derfuss T; Kappos L; Granziera C; Wuerfel J; Magon S; Yaldizli Ö
J Neurol; 2020 Jan; 267(1):192-202. PubMed ID: 31612322
[TBL] [Abstract][Full Text] [Related]
25. Cortical neuronal densities and cerebral white matter demyelination in multiple sclerosis: a retrospective study.
Trapp BD; Vignos M; Dudman J; Chang A; Fisher E; Staugaitis SM; Battapady H; Mork S; Ontaneda D; Jones SE; Fox RJ; Chen J; Nakamura K; Rudick RA
Lancet Neurol; 2018 Oct; 17(10):870-884. PubMed ID: 30143361
[TBL] [Abstract][Full Text] [Related]
26. High field (9.4 Tesla) magnetic resonance imaging of cortical grey matter lesions in multiple sclerosis.
Schmierer K; Parkes HG; So PW; An SF; Brandner S; Ordidge RJ; Yousry TA; Miller DH
Brain; 2010 Mar; 133(Pt 3):858-67. PubMed ID: 20123726
[TBL] [Abstract][Full Text] [Related]
27. Heterogeneous pathological processes account for thalamic degeneration in multiple sclerosis: Insights from 7 T imaging.
Louapre C; Govindarajan ST; Giannì C; Madigan N; Sloane JA; Treaba CA; Herranz E; Kinkel RP; Mainero C
Mult Scler; 2018 Oct; 24(11):1433-1444. PubMed ID: 28803512
[TBL] [Abstract][Full Text] [Related]
28. Sample size requirements for one-year treatment effects using deep gray matter volume from 3T MRI in progressive forms of multiple sclerosis.
Kim G; Chu R; Yousuf F; Tauhid S; Stazzone L; Houtchens MK; Stankiewicz JM; Severson C; Kimbrough D; Quintana FJ; Chitnis T; Weiner HL; Healy BC; Bakshi R
Int J Neurosci; 2017 Nov; 127(11):971-980. PubMed ID: 28100092
[TBL] [Abstract][Full Text] [Related]
29. Cortical atrophy patterns in multiple sclerosis are non-random and clinically relevant.
Steenwijk MD; Geurts JJ; Daams M; Tijms BM; Wink AM; Balk LJ; Tewarie PK; Uitdehaag BM; Barkhof F; Vrenken H; Pouwels PJ
Brain; 2016 Jan; 139(Pt 1):115-26. PubMed ID: 26637488
[TBL] [Abstract][Full Text] [Related]
30. Lymphotoxin-alpha expression in the meninges causes lymphoid tissue formation and neurodegeneration.
James Bates RE; Browne E; Schalks R; Jacobs H; Tan L; Parekh P; Magliozzi R; Calabrese M; Mazarakis ND; Reynolds R
Brain; 2022 Dec; 145(12):4287-4307. PubMed ID: 35776111
[TBL] [Abstract][Full Text] [Related]
31. Complement activation in multiple sclerosis plaques: an immunohistochemical analysis.
Ingram G; Loveless S; Howell OW; Hakobyan S; Dancey B; Harris CL; Robertson NP; Neal JW; Morgan BP
Acta Neuropathol Commun; 2014 May; 2():53. PubMed ID: 24887075
[TBL] [Abstract][Full Text] [Related]
32. Tissue damage detected by quantitative gradient echo MRI correlates with clinical progression in non-relapsing progressive MS.
Xiang B; Brier MR; Kanthamneni M; Wen J; Snyder AZ; Yablonskiy DA; Cross AH
Mult Scler; 2022 Sep; 28(10):1515-1525. PubMed ID: 35196933
[TBL] [Abstract][Full Text] [Related]
33. Vulnerability of Thalamic Nuclei at CSF Interface During the Entire Course of Multiple Sclerosis.
Koubiyr I; Yamamoto T; Blyau S; Kamroui RA; Mansencal B; Planche V; Petit L; Saranathan M; Casey R; Ruet A; Brochet B; Manjón JV; Dousset V; Coupé P; Tourdias T;
Neurol Neuroimmunol Neuroinflamm; 2024 May; 11(3):e200222. PubMed ID: 38635941
[TBL] [Abstract][Full Text] [Related]
34. Analysis of ageing-associated grey matter volume in patients with multiple sclerosis shows excess atrophy in subcortical regions.
Bishop CA; Newbould RD; Lee JS; Honeyfield L; Quest R; Colasanti A; Ali R; Mattoscio M; Cortese A; Nicholas R; Matthews PM; Muraro PA; Waldman AD
Neuroimage Clin; 2017; 13():9-15. PubMed ID: 27896065
[TBL] [Abstract][Full Text] [Related]
35. Demyelination, inflammation, and neurodegeneration in multiple sclerosis deep gray matter.
Vercellino M; Masera S; Lorenzatti M; Condello C; Merola A; Mattioda A; Tribolo A; Capello E; Mancardi GL; Mutani R; Giordana MT; Cavalla P
J Neuropathol Exp Neurol; 2009 May; 68(5):489-502. PubMed ID: 19525897
[TBL] [Abstract][Full Text] [Related]
36. B cell rich meningeal inflammation associates with increased spinal cord pathology in multiple sclerosis.
Reali C; Magliozzi R; Roncaroli F; Nicholas R; Howell OW; Reynolds R
Brain Pathol; 2020 Jul; 30(4):779-793. PubMed ID: 32243032
[TBL] [Abstract][Full Text] [Related]
37. Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis.
Gaetano L; Häring DA; Radue EW; Mueller-Lenke N; Thakur A; Tomic D; Kappos L; Sprenger T
Neurology; 2018 Apr; 90(15):e1324-e1332. PubMed ID: 29540589
[TBL] [Abstract][Full Text] [Related]
38. Volume loss in the deep gray matter and thalamic subnuclei: a longitudinal study on disability progression in multiple sclerosis.
Magon S; Tsagkas C; Gaetano L; Patel R; Naegelin Y; Amann M; Parmar K; Papadopoulou A; Wuerfel J; Stippich C; Kappos L; Chakravarty MM; Sprenger T
J Neurol; 2020 May; 267(5):1536-1546. PubMed ID: 32040710
[TBL] [Abstract][Full Text] [Related]
39. Evidence for early neurodegeneration in the cervical cord of patients with primary progressive multiple sclerosis.
Abdel-Aziz K; Schneider T; Solanky BS; Yiannakas MC; Altmann DR; Wheeler-Kingshott CA; Peters AL; Day BL; Thompson AJ; Ciccarelli O
Brain; 2015 Jun; 138(Pt 6):1568-82. PubMed ID: 25863355
[TBL] [Abstract][Full Text] [Related]
40. Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial.
Arnold DL; Piani-Meier D; Bar-Or A; Benedict RH; Cree BA; Giovannoni G; Gold R; Vermersch P; Arnould S; Dahlke F; Hach T; Ritter S; Karlsson G; Kappos L; Fox RJ;
Mult Scler; 2022 Sep; 28(10):1526-1540. PubMed ID: 35261318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
